Exhibit 99.1

    BUSINESS OUTSOURCES SERVICES INC. ANNOUNCES LETTER OF INTENT TO NEGOTIATE
       AUTOLOGOUS INSULIN PRODUCING CELLS (AIPC) REGENERATION TECHNOLOGY.

TEL AVIV, ISRAEL,  AUGUST 5, 2011 - Business  Outsourcing,  Inc., (OTCBB:  BOUT)
announces that is has signed a letter of intent with Prof.  Sarah Ferber and Ms.
Vered  Caplan  to have  them use  their  best  efforts  to  negotiate  a license
agreement on behalf of the Company with the Sheba Medical  Center to acquire the
exclusive rights to their functional  autologous  insulin producing cells (AIPC)
regeneration technology.

Prof.  Sarah  Ferber  Ph.D in  Medical  Science,  is the  head of the  Molecular
Endocrinology research unit at the Sheba Medical Center at Tel Hashomer hospital
in Israel.  For the last thirteen  years, on behalf of the Sheba Medical Center,
Prof. Ferber has developed this unique technology,  substituting  malfunctioning
organs with new  functional  tissues  created  from the  patient's  own existing
organs. The methodology has been patented in the United States,  Europe,  Japan,
Canada and Australia.

Medical  experts  and  scientists  have  stated  that  Sheba  Medical   Center's
technology,  currently in its developmental  stage, could be pivotal in diabetes
treatment.  Prof.  Ferber's work has been published in the most highly  regarded
scientific  journals  such  as  Nature  Medicine,  JBC,  PNAS,  Annual  Reviews,
Autoimmunity  Journal and more.  If the letter of intent can be acted upon and a
license agreement reached, it would be Business  Outsourcing Inc.'s intention to
bring this technology to the clinical stage.

As part of the  transaction,  Prof.  Ferber and Ms. Caplan would have consulting
contracts to develop the project that would include  options to purchase  common
stock  in  the  Company.  The  Company  would  have  to  arrange  financing  and
restructure its capital.  Further, as part of the transaction,  the Company will
change its name to Orgenesis  Inc. and conduct a 35 for one forward split of its
common stock.

Closing of the  intended  transaction  is  conditional  on getting  approval and
agreement by the Sheba Medical  Center,  completion  and agreement of consulting
and other documents, due diligence and other conditions.

ON BEHALF OF THE BOARD
BUSINESS OUTSOURCING SERVICES INC.
"Guilbert Cuison"
Guilbert Cuison
President and Director

DISCLAIMER FOR FORWARD-LOOKING INFORMATION

Certain statements in this news release are  forward-looking  statements,  which
reflect the  expectations  of management  regarding  the Company's  intention to
enter into a license  agreement,  develop the AIPC  regeneration  technology and
employ certain persons to develop the project,  and that the technology could be
pivotal  for  diabetes  treatment.  Such  statements  are  subject  to risks and
uncertainties  that may cause actual  results,  performance or  developments  to
differ  materially from those  contained in the statements.  No assurance can be
given that any of the events anticipated by the forward-looking  statements will
occur or, if they do occur,  what  benefits the Company will obtain from them. A
number of risks and  uncertainties  could  cause our  actual  results  to differ
materially  from those expressed or implied by the  forward-looking  statements,
including:  our failure to agree with other parties to enter into  agreements as
contemplated;  our failure  develop the AIPC  regeneration  technology,  for any
reason,   our  ability  to  raise  the  funds  necessary  to  develop  the  AIPC
regeneration technology,  competition from other forms of therapy; and inability
to  meet   compliance   with   all   required   government   regulation.   These
forward-looking  statements  are made as of the date of this news  release  and,
except as required by law,  the Company  assumes no  obligation  to update these
forward-looking statements, or to update the reasons why actual results differed
from those projected in the forward-looking statements.